NCT01720225View on ClinicalTrials.gov

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

November 6, 2012

Primary Completion Date

January 8, 2020

Study Completion Date

January 8, 2020

Conditions
Leukemia
Interventions
DRUG

Decitabine

20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.

DRUG

Azacitidine

75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01720225 - Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | Biotech Hunter | Biotech Hunter